| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
GSK-3β (Glycogen Synthase Kinase-3β): Blumenol B exerts its anti-tumor effects by activating GSK-3β, promoting the degradation of cyclin D1 and c-Myc.
Wnt/β-catenin Signaling Pathway: This compound inhibits the Wnt/β-catenin signaling pathway, further contributing to its anti-tumor effects.
Mitochondria: Blumenol B localizes mainly to mitochondria, where it disrupts mitochondrial activity and induces apoptosis in cancer cells.
|
|---|---|
| ln Vitro |
Antimicrobial Activity: Blumenol B exhibits antimicrobial activity against Escherichia coli and Bacillus subtilis. At a concentration of 200 μg/mL, it produces an inhibition zone diameter of 10 mm against E. coli and 12 mm against B. subtilis.
Antitumor Activity: As a differentiation-inducing factor (DIF-3 analog), Blumenol B activates GSK-3β, facilitating the degradation of cyclin D1 and c-Myc, resulting in reduced expression levels of these proteins, thereby inhibiting cell proliferation and inducing cell cycle arrest. This compound also induces apoptosis in cancer cells by disrupting mitochondrial activity.
Antioxidant Activity: Blumenol B isolated from Croton lechleri latex, together with other compounds, was evaluated for in vitro antioxidant activity using DPPH, total antioxidant capacity, and lipid peroxidation assays.
Anti-inflammatory Activity: In an LPS-stimulated RAW 264.7 macrophage model, related compounds (e.g., gallic acid) exhibited inhibitory activity on nitric oxide production at a concentration of 25 μM, although the specific activity data for Blumenol B were not detailed in this study.
|
| Cell Assay |
Antimicrobial Activity Assessment: The antimicrobial activity of Blumenol B is evaluated using the agar diffusion method. Blumenol B at a concentration of 200 μg/mL is added to agar plates containing Escherichia coli or Bacillus subtilis. After incubation, the inhibition zone diameter is measured to assess the antimicrobial effect.
Anti-inflammatory Activity Assessment: The anti-inflammatory activity of compounds is evaluated using an LPS-stimulated RAW 264.7 macrophage model. Cells are incubated with test compounds (e.g., at 25 μM concentration), and nitric oxide production in the cell culture supernatant is detected using the Griess method.
|
| References | |
| Additional Infomation |
Ibuprofen B has been reported in tea trees, amla, and other organisms with available data.
|
| Molecular Formula |
C13H22O3
|
|---|---|
| Molecular Weight |
226.31
|
| Exact Mass |
226.156
|
| CAS # |
36151-01-6
|
| PubChem CID |
14135402
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.0±0.1 g/cm3
|
| Boiling Point |
359.1±42.0 °C at 760 mmHg
|
| Flash Point |
185.1±24.4 °C
|
| Vapour Pressure |
0.0±1.8 mmHg at 25°C
|
| Index of Refraction |
1.494
|
| LogP |
0.91
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
16
|
| Complexity |
317
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
O[C@@]1(C(C)=CC(CC1(C)C)=O)CC[C@@H](C)O
|
| InChi Key |
CWOFGGNDZOPNFG-ZWNOBZJWSA-N
|
| InChi Code |
InChI=1S/C13H22O3/c1-9-7-11(15)8-12(3,4)13(9,16)6-5-10(2)14/h7,10,14,16H,5-6,8H2,1-4H3/t10-,13-/m1/s1
|
| Chemical Name |
(4S)-4-hydroxy-4-[(3R)-3-hydroxybutyl]-3,5,5-trimethylcyclohex-2-en-1-one
|
| Synonyms |
RefChem:1080049; (6R,9RS)-7,8-dihydro-6,9-dihydroxy-9-apo-epsilonn-caroten-3-one; (4S)-4-hydroxy-4-((3R)-3-hydroxybutyl)-3,5,5-trimethylcyclohex-2-en-1-one; 36151-01-6; Blumenol B;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
|---|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.4187 mL | 22.0936 mL | 44.1872 mL | |
| 5 mM | 0.8837 mL | 4.4187 mL | 8.8374 mL | |
| 10 mM | 0.4419 mL | 2.2094 mL | 4.4187 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
